BioSpace News Archive

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to a non-executive employee to purchase an aggregate of 10,000 shares of common stock.

RadioMedix, Inc., a clinical-stage biotechnology company announced an agreement with an entity related to Portland Investment Counsel Inc. involving an equity investment of $40 million Series A funding round.

Bone Biologics Corporation announces the pricing of an underwritten public offering of 3,777,778 units of securities at an offering price of $1.35 per unit, for total gross proceeds of $5,100,000 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Pharvaris announced the presentation of preclinical and clinical data of PHA121, and its two formulations – softgel capsule PHVS416 and extended-release tablet PHVS719, for the treatment of HAE at the 2022 HAEi Global Leadership Workshop being held October 6-9, 2022, in Frankfurt, Germany.

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 6-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon.

Aditxt, Inc.’s AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19.

Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics today announced that it has submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its novel neuropsychiatric cannabinoid therapy.

Pfizer Canada ULC and BioNTech SE today announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5 as a 30-μg booster dose for individuals ages 12 years and older.

Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company”), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) pursuant to the terms of the Company’s Stock Option Plan.

Global manufacturer and distributor of high-quality airway and respiratory products, Pulmodyne, Inc., and fluidics-based MedTech company, fluidIQ, Inc., announced today a global licensing and joint research and development agreement.